Steatorrhea surgery
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Surgery is usually reserved for patients with refractory or pre-malignant complications, such as Enteropathy Associated T-cell Lymphoma (EATL) and ulcerative jejunitis (UJ). EATL patients presenting with ulcerative lesions, stenotic lesions, and perforation needs surgical intervention. Surgery also serves as a pre-therapy in order to prevent perforation of the small bowel during chemotherapy in case of EATL. After surgery patients receive immunotherapy, chemotherapy and/or stem cell transplantation.
Surgery
Surgery is usually reserved for patients with refractory or pre-malignant complications, such as Enteropathy Associated T-cell Lymphoma (EATL) and ulcerative jejunitis (UJ). EATL patients presenting with ulcerative lesions, stenotic lesions, and perforation needs surgical intervention. Surgery also serves as a pre-therapy in order to prevent perforation of the small bowel during chemotherapy in case of EATL. After surgery patients receive immunotherapy, chemotherapy and/or stem cell transplantation.[1][2][3]
References
- ↑ van de Water JM, Nijeboer P, de Baaij LR, Zegers J, Bouma G, Visser OJ, van der Peet DL, Mulder CJ, Meijerink WJ (2015). “Surgery in (pre)malignant celiac disease”. World J. Gastroenterol. 21 (43): 12403–9. doi:10.3748/wjg.v21.i43.12403. PMC 4649123. PMID 26604647.
- ↑ Han SL, Cheng J, Zhou HZ, Guo SC, Jia ZR, Wang PF (2010). “Surgically treated primary malignant tumor of small bowel: a clinical analysis”. World J. Gastroenterol. 16 (12): 1527–32. PMC 2846261. PMID 20333796.
- ↑ Di Sabatino A, Biagi F, Gobbi PG, Corazza GR (2012). “How I treat enteropathy-associated T-cell lymphoma”. Blood. 119 (11): 2458–68. doi:10.1182/blood-2011-10-385559. PMID 22271451.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH